Sonoma Pharmaceuticals, Inc. (SNOA)
1.13
+0.02
(+1.80%)
USD |
NASDAQ |
Nov 09, 11:35
Sonoma Pharmaceuticals Enterprise Value : 0.7132M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 0.7132M |
| November 05, 2026 | 0.5218M |
| November 04, 2026 | 0.7132M |
| November 03, 2026 | 0.8568M |
| November 02, 2026 | 0.6654M |
| October 30, 2026 | 0.6654M |
| October 29, 2026 | 1.144M |
| October 28, 2026 | 0.8568M |
| October 27, 2026 | 0.9047M |
| October 26, 2026 | 0.7611M |
| October 23, 2026 | 0.7132M |
| October 22, 2026 | 0.9047M |
| October 21, 2026 | 0.8568M |
| October 20, 2026 | 0.9047M |
| October 19, 2026 | 0.7611M |
| October 16, 2026 | 0.7611M |
| October 15, 2026 | 0.9047M |
| October 14, 2026 | 0.9525M |
| October 13, 2026 | 1.048M |
| October 12, 2026 | 1.288M |
| October 09, 2026 | 1.288M |
| October 08, 2026 | 0.9525M |
| October 07, 2026 | 1.240M |
| October 06, 2026 | 1.288M |
| October 05, 2026 | 1.240M |
| Date | Value |
|---|---|
| October 02, 2026 | 1.335M |
| October 01, 2026 | 1.383M |
| September 30, 2026 | 1.527M |
| September 29, 2026 | 1.359M |
| September 28, 2026 | 1.431M |
| September 25, 2026 | 1.479M |
| September 24, 2026 | 1.359M |
| September 23, 2026 | 1.383M |
| September 22, 2026 | 1.599M |
| September 21, 2026 | 1.383M |
| September 18, 2026 | 1.527M |
| September 17, 2026 | 1.431M |
| September 16, 2026 | 1.288M |
| September 15, 2026 | 1.527M |
| September 14, 2026 | 1.575M |
| September 11, 2026 | 1.646M |
| September 10, 2026 | 1.670M |
| September 09, 2026 | 1.622M |
| September 08, 2026 | 1.766M |
| September 04, 2026 | 1.742M |
| September 03, 2026 | 1.718M |
| September 02, 2026 | 1.575M |
| September 01, 2026 | 1.575M |
| August 31, 2026 | 1.575M |
| August 28, 2026 | 1.670M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.715B |
| Corcept Therapeutics, Inc. | 7.597B |
| Veru, Inc. | 13.04M |
| Johnson & Johnson | 692.32B |
| Eli Lilly & Co. | 1.319T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.33M |
| Revenue (Quarterly) | 6.406M |
| Total Expenses (Quarterly) | 6.736M |
| EPS Diluted (Quarterly) | -0.0858 |
| Gross Profit Margin (Quarterly) | 40.23% |
| Profit Margin (Quarterly) | -5.15% |
| Earnings Yield | -107.8% |
| Normalized Earnings Yield | -107.75 |